Overview

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety and efficacy of a lower dose of dalfampridine extended release tablets compared to the currently approved dose in improving walking in Multiple Sclerosis (MS) patients.
Phase:
Phase 3
Details
Lead Sponsor:
Acorda Therapeutics
Treatments:
4-Aminopyridine